- New di(hetero)arylethers and di(hetero)arylamines in the thieno[3,2-b]pyridine series: Synthesis, growth inhibitory activity on human tumor cell lines and non-tumor cells, effects on cell cycle and on programmed cell death
-
New fluorinated and methoxylated di(hetero)arylethers and di(hetero)arylamines were prepared functionalizing the 7-position of the thieno[3,2-b]pyridine, using copper (C-O) or palladium (C-N) catalyzed couplings, respectively, of the 7-bromothieno[3,2-b]pyridine, also prepared, with ortho, meta and para fluoro or methoxy phenols and anilines. The compounds obtained were evaluated for their growth inhibitory activity on the human tumor cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), HCT15 (colon carcinoma), HepG2 (hepatocellular carcinoma) and HeLa (cervical carcinoma). The most active compounds, a di(hetero)arylether with a methoxy group in the meta position relative to the ether function and two di(hetero)arylamines with a methoxy group either in the ortho or in the meta position relative to the NH, were further tested at their GI50 concentrations on NCI-H460 cells causing pronounced alterations in the cell cycle profile and a strong and significant increase in the programmed death of these cells. The fluorinated and the other methoxylated compounds did not show important activity, presenting high GI50 values in all the cell lines tested. Furthermore, the hepatotoxicity of the compounds was assessed using porcine liver primary cells (PLP2), established by some of us. Results showed that one of the most active compounds was not toxic to the non-tumor cells at their GI50 concentrations showing to be the most promising as antitumoral.
- Queiroz, Maria-Jo?o R.P.,Peixoto, Daniela,Calhelha, Ricardo C.,Soares, Pedro,Dos Santos, Tiago,Lima, Raquel T.,Campos, Joana F.,Abreu, Rui M.V.,Ferreira, Isabel C.F.R.,Vasconcelos, M. Helena
-
-
Read Online
- MODULATORS OF THE NMDA RECEPTOR
-
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
- -
-
Page/Page column 30; 45; 76-77
(2021/01/23)
-
- EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS
-
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
- -
-
Paragraph 0311-0312; 0339; 0365
(2021/01/23)
-
- PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
-
The present invention is directed to novel prodrugs of modulators of the NMDA receptor of formula I. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
- -
-
Page/Page column 100
(2021/01/23)
-
- THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS
-
The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
- -
-
Page/Page column 25
(2008/06/13)
-
- IMIDAZOPYRIDAZINE COMPOUNDS
-
The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
- -
-
Page/Page column 89
(2008/06/13)
-
- PURINE DERIVATIVES AS KINASE INHIBITORS
-
The present invention provides kinase inhibitors of Formula I.
- -
-
Page/Page column 60
(2008/06/13)
-